|
1
|
Moore DD and Luu HH: Osteosarcoma. Cancer
Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
He JP, Hao Y, Wang XL, Yang XJ, Shao JF,
Guo FJ and Feng JX: Review of the molecular pathogenesis of
osteosarcoma. Asian Pac J Cancer Prev. 15:5967–5976. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Allison DC, Carney SC, Ahlmann ER,
Hendifar A, Chawla S, Fedenko A, Angeles C and Menendez LR: A
meta-analysis of osteosarcoma outcomes in the modern medical era.
Sarcoma. 2012:7048722012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baumhoer D: Molecular characterization of
osteosarcomas. Pathologe. 34:(Suppl 2). 260–263. 2013.(In German).
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ho RH and Kim RB: Transporters and drug
therapy: Implications for drug disposition and disease. Clin
Pharmacol Ther. 78:260–277. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abdulhussein AA and Wallace HM: Polyamines
and membrane transporters. Amino Acids. 46:655–660. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zinzi L, Contino M, Cantore M, Capparelli
E, Leopoldo M and Colabufo NA: ABC transporters in CSC membranes as
a novel target for treating tumor relapse. Front Pharmacol.
5:1632014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu FH and Catterall WA: The VGL-chanome: A
protein superfamily specialized for electrical signaling and ionic
homeostasis. Sci STKE. 2004:re152004.PubMed/NCBI
|
|
10
|
Montanari F and Ecker GF: Prediction of
drug-ABC-transporter interaction - Recent advances and future
challenges. Adv Drug Deliv Rev. 86:17–26. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang F, Feng XC, Li YM, Yang H and Ma TH:
Aquaporins as potential drug targets. Acta Pharmacol Sin.
27:395–401. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dunbar LA and Caplan MJ: Ion pumps in
polarized cells: Sorting and regulation of the Na+,
K+- and H+, K+-ATPases. J Biol
Chem. 276:29617–29620. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fredriksson R, Nordström KJ, Stephansson
O, Hägglund MG and Schiöth HB: The solute carrier (SLC) complement
of the human genome: Phylogenetic classification reveals four major
families. FEBS Lett. 582:3811–3816. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Martens-de Kemp SR, Brink A, Stigter-van
Walsum M, Damen JM, Rustenburg F, Wu T, van Wieringen WN,
Schuurhuis GJ, Braakhuis BJ, Slijper M, et al: CD98 marks a
subpopulation of head and neck squamous cell carcinoma cells with
stem cell properties. Stem Cell Res (Amst). 10:477–488. 2013.
View Article : Google Scholar
|
|
15
|
Kaira K, Sunose Y, Oriuchi N, Kanai Y and
Takeyoshi I: CD98 is a promising prognostic biomarker in biliary
tract cancer. Hepatobiliary Pancreat Dis Int. 13:654–657. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fei F, Li X, Xu L, Li D, Zhang Z, Guo X,
Yang H, Chen Z and Xing J: CD147-CD98hc complex contributes to poor
prognosis of non-small cell lung cancer patients through promoting
cell proliferation via the PI3K/Akt signaling pathway. Ann Surg
Oncol. 21:4359–4368. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Furuya M, Horiguchi J, Nakajima H, Kanai Y
and Oyama T: Correlation of L-type amino acid transporter 1 and
CD98 expression with triple negative breast cancer prognosis.
Cancer Sci. 103:382–389. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin S, Guo Q, Wen J, Li C, Lin J, Cui X,
Sang N and Pan J: Survival analyses correlate stanniocalcin 2
overexpression to poor prognosis of nasopharyngeal carcinomas. J
Exp Clin Cancer Res. 33:262014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He L, Vasiliou K and Nebert DW: Analysis
and update of the human solute carrier (SLC) gene superfamily. Hum
Genomics. 3:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Babu E, Bhutia YD, Ramachandran S,
Gnanaprakasam JP, Prasad PD, Thangaraju M and Ganapathy V: Deletion
of the amino acid transporter Slc6a14 suppresses tumour growth in
spontaneous mouse models of breast cancer. Biochem J. 469:17–23.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen X, Zhang L, Ren S, Li X, Zhou F, Li
W, Gao G, He Y and Zhou C: Genomic polymorphisms of SLC29A3
associated with overall survival in advanced non-small-cell lung
cancer treated with gemcitabine. Med Oncol. 31:8652014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Salaün C, Leroy C, Rousseau A, Boitez V,
Beck L and Friedlander G: Identification of a novel
transport-independent function of PiT1/SLC20A1 in the regulation of
TNF-induced apoptosis. J Biol Chem. 285:34408–34418. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Garber ME, Troyanskaya OG, Schluens K,
Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen
GD, Perou CM, Whyte RI, et al: Diversity of gene expression in
adenocarcinoma of the lung. Proc Natl Acad Sci USA. 98:13784–13789.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prager GW, Poettler M, Schmidinger M,
Mazal PR, Susani M, Zielinski CC and Haitel A: CD98hc (SLC3A2), a
novel marker in renal cell cancer. Eur J Clin Invest. 39:304–310.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang Y, Toy W, Choong LY, Hou P, Ashktorab
H, Smoot DT, Yeoh KG and Lim YP: Discovery of SLC3A2 cell membrane
protein as a potential gastric cancer biomarker: Implications in
molecular imaging. J Proteome Res. 11:5736–5747. 2012.PubMed/NCBI
|
|
26
|
Wu B, Wang Y, Yang XM, Xu BQ, Feng F, Wang
B, Liang Q, Li Y, Zhou Y, Jiang JL, et al: Basigin-mediated
redistribution of CD98 promotes cell spreading and tumorigenicity
in hepatocellular carcinoma. J Exp Clin Cancer Res. 34:1102015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cantor J, Browne CD, Ruppert R, Féral CC,
Fässler R, Rickert RC and Ginsberg MH: CD98hc facilitates B cell
proliferation and adaptive humoral immunity. Nat Immunol.
10:412–419. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cantor J, Slepak M, Ege N, Chang JT and
Ginsberg MH: Loss of T cell CD98 H chain specifically ablates T
cell clonal expansion and protects from autoimmunity. J Immunol.
187:851–860. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fogelstrand P, Féral CC, Zargham R and
Ginsberg MH: Dependence of proliferative vascular smooth muscle
cells on CD98hc (4F2hc, SLC3A2). J Exp Med. 206:2397–2406. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nguyen HT, Dalmasso G, Torkvist L,
Halfvarson J, Yan Y, Laroui H, Shmerling D, Tallone T, D'Amato M,
Sitaraman SV, et al: CD98 expression modulates intestinal
homeostasis, inflammation, and colitis-associated cancer in mice. J
Clin Invest. 121:1733–1747. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Feral CC, Nishiya N, Fenczik CA, Stuhlmann
H, Slepak M and Ginsberg MH: CD98hc (SLC3A2) mediates integrin
signaling. Proc Natl Acad Sci USA. 102:355–360. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bulus N, Feral C, Pozzi A and Zent R: CD98
increases renal epithelial cell proliferation by activating MAPKs.
PLoS One. 7:e400262012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Montero JC, Esparís-Ogando A, Re-Louhau
MF, Seoane S, Abad M, Calero R, Ocaña A and Pandiella A: Active
kinase profiling, genetic and pharmacological data define mTOR as
an important common target in triple-negative breast cancer.
Oncogene. 33:148–156. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yao W, Guan M, Jia J, Dai W, Lay YA,
Amugongo S, Liu R, Olivos D, Saunders M, Lam KS, et al: Reversing
bone loss by directing mesenchymal stem cells to bone. Stem Cells.
31:2003–2014. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Porta C, Paglino C and Mosca A: Targeting
PI3K/Akt/mTOR Signaling in Cancer. Front Oncol. 4:642014.
View Article : Google Scholar : PubMed/NCBI
|
